Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Japan's IP Court Awards Record $150M in Landmark Pharma Patent Case: Toray vs. Generics
Hot Spotlight
5 min read
Japan's IP Court Awards Record $150M in Landmark Pharma Patent Case: Toray vs. Generics
10 June 2025
A landmark ruling by Japan’s IP High Court awarded record-breaking $150 million damages in the Nalfurafine (Remitch®) patent dispute. This case reshapes how pharmaceutical companies approach patent term extensions, generic entry strategies, and IP litigation risks.
Read →
May 2025 Patent Highlights: LP(a) inhibitor from CSPC is better?
May 2025 Patent Highlights: LP(a) inhibitor from CSPC is better?
10 June 2025
YS2302018 was discovered by CSPC and has been shown to effectively prevent the formation of Lp(a).
Read →
May 2025 Patent Highlights: Eli Lilly’s CRHR2 peptide agonists
May 2025 Patent Highlights: Eli Lilly’s CRHR2 peptide agonists
10 June 2025
Tirzepatide is not Lilly’s only contender in this field; its small-molecule agonist orforglipron also met primary endpoints in studies and is poised for regulatory submission and potential approval.
Read →
May 2025 Patent Highlights: Roche's tri-complex inhibitors
May 2025 Patent Highlights: Roche's tri-complex inhibitors
10 June 2025
F.Hoffmann-La Roche(Roche) disclosed two patent applications, WO2025093625A1 and WO2025104149A1, covering a series of novel macrocyclic KRAS G12C inhibitors.
Read →
May 2025 Patent Highlights: Eisbach’s ALC1 inhibitor
May 2025 Patent Highlights: Eisbach’s ALC1 inhibitor
10 June 2025
Eisbach Bio GmbH has disclosed two patent applications primarily focused on the use of ALC1 inhibitors in cancer treatment: WO2025088087A1 and WO2025088175A1.
Read →
May 2025 Patent Highlights: Monte Rosa's CDK2 molecular glue degraders
May 2025 Patent Highlights: Monte Rosa's CDK2 molecular glue degraders
10 June 2025
A recent Monte Rosa patent application (WO2025090727) covers eight compounds and reveals the possible structure of MRT-9643 (CDK2 MGD) (compound 6).
Read →
May 2025 Patent Highlights: Vertex’s NaV Inhibitors
May 2025 Patent Highlights: Vertex’s NaV Inhibitors
10 June 2025
Suzetrigine is the first non-opioid novel pain medication approved in over two decades for pain management; however, its efficacy appears to be limited.
Read →
Hiro-LS Evolves into Patsnap Eureka LS - The Era of Biopharma AI Agents Begins Now
Feature Updates
3 min read
Hiro-LS Evolves into Patsnap Eureka LS - The Era of Biopharma AI Agents Begins Now
9 June 2025
Patsnap Eureka LS marks our transformation from a large language model into an intelligent AI Agent platform, purpose-built for the biopharmaceutical industry.
Read →
Patent Drafting Pitfalls: Alnylam's Custom Definition Sinks COVID-19 Vaccine Lawsuit
Hot Spotlight
5 min read
Patent Drafting Pitfalls: Alnylam's Custom Definition Sinks COVID-19 Vaccine Lawsuit
6 June 2025
On June 4, 2025, the CAFC issued a precedential decision in a patent infringement case involving mRNA-based COVID-19 vaccines, addressing whether the patentee’s “custom” definition of a term constituted infringement.
Read →
The Radiopharmaceutical Revolution: Transforming Precision Diagnosis to Personalized Therapy
Hot Spotlight
12 min read
The Radiopharmaceutical Revolution: Transforming Precision Diagnosis to Personalized Therapy
9 May 2025
Radiopharmaceuticals, which combine radioactive isotopes with specific molecular carriers, are ushering in a new era of personalized medicine.
Read →
Unlocking the Potential of CLDN18.2: Innovations in Antibody-Drug Conjugates for GI Cancers
Hot Spotlight
12 min read
Unlocking the Potential of CLDN18.2: Innovations in Antibody-Drug Conjugates for GI Cancers
29 April 2025
In 2024, the field of cancer therapeutics has witnessed remarkable progress in targeting Claudin 18.2 (CLDN18.2).
Read →
From Courtrooms to Compliance: Johnson & Johnson’s Fight to Survive the Talc Powder Scandal
Hot Spotlight
20 min read
From Courtrooms to Compliance: Johnson & Johnson’s Fight to Survive the Talc Powder Scandal
28 April 2025
Johnson & Johnson was swept into a mounting legal crisis centered on allegations that its talc-based products caused cancer.
Read →